Segway Powersports to Present Flagship Super Villain SX20T and AT10 W MUD at 139th Canton Fair

Segway Powersports to Present Flagship Super Villain SX20T and AT10 W MUD at 139th Canton Fair

GUANGZHOU, China, April 10, 2026 /PRNewswire/ -- Segway Powersports, a global innovator in intelligent off-road vehicles and connected riding systems, is set to showcase its flagship products, the Super Villain SX20T and AT10 W MUD, at the 139th...

Portrai to Present 11 Posters on AI-Driven Spatial Transcriptomics at AACR 2026

Portrai to Present 11 Posters on AI-Driven Spatial Transcriptomics at AACR 2026

The South Korean spatial biology company unveils new AI agents, foundation models, and spatial biomarkers for oncology drug discovery. SEOUL, South Korea, April 8, 2026 /PRNewswire/ -- Portrai, Inc. today announced it will present 11 posters...

Korea's AI-Driven Healthcare Technologies Take Centre Stage at the upcoming WHX Bangkok 2026

Korea's AI-Driven Healthcare Technologies Take Centre Stage at the upcoming WHX Bangkok 2026

BANGKOK, April 3, 2026 /PRNewswire/ -- WHX Bangkok 2026 organised by Informa Markets is set to be a landmark trade event for showcasing Korea's groundbreaking advancements in AI-driven healthcare and technology. Two leading Korean companies, Korea...

Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions

Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions

Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions. The presentation will...

Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study

Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study

CHENGDU, China, March 18, 2026 /PRNewswire/ -- The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study...

Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs

Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs

SHANGHAI and HONG KONG, March 18, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...

Nota AI to Showcase End-to-End On-Device AI-from Edge Optimization to Real-World Industrial Deployment-at Embedded World 2026

Nota AI to Showcase End-to-End On-Device AI-from Edge Optimization to Real-World Industrial Deployment-at Embedded World 2026

Over 40 AI models lightweighted and optimized across more than 100 devices; technologies adopted by global leaders including Samsung and NVIDIA Live demonstrations of LLM and computer vision models running in real time on Qualcomm and Arm hardware,...

Direct Genome-Scale Mapping of Endonuclease Activity of the Human LINE-1 ORF2p Endonuclease

Direct Genome-Scale Mapping of Endonuclease Activity of the Human LINE-1 ORF2p Endonuclease

Nabsys and the Research Lab of Dr. Martin Taylor, Brown University, Present Data Using the OhmX™ Platform at AGBT 2026 PROVIDENCE, R.I., Feb. 25, 2026 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping (EGM) technology,...

U Power to Present at OTC Markets AI & Technology Investor Conference on February 19

U Power to Present at OTC Markets AI & Technology Investor Conference on February 19

BANGKOK, Feb. 14, 2026 /PRNewswire/ -- U Power Limited (Nasdaq: UCAR) ("U Power" or the "Company"), a provider of AI-integrated solutions for next-generation energy grids and intelligent transportation systems, today announced that its management...

QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results

QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results

SHANGHAI, Jan. 29, 2026 /PRNewswire/ -- QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders,...

  • 1
  • 2
  • 3
  • 4
  • 5
  • menu
    menu